Sinco Pharmaceutical Holdings (HKSE:06833) COGS-to-Revenue : 0.88 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings COGS-to-Revenue?

Sinco Pharmaceutical Holdings's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$1,399 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$1,586 Mil.

Sinco Pharmaceutical Holdings's COGS to Revenue for the six months ended in Dec. 2023 was 0.88.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Sinco Pharmaceutical Holdings's Gross Margin % for the six months ended in Dec. 2023 was 11.78%.

Sinco Pharmaceutical Holdings COGS-to-Revenue Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings COGS-to-Revenue Chart

Sinco Pharmaceutical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.81

0.87

0.82

0.87

Sinco Pharmaceutical Holdings Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial														0.82	0.83	0.90	0.86	0.88

Sinco Pharmaceutical Holdings COGS-to-Revenue Calculation

Sinco Pharmaceutical Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2424.67	/	2778.267
	=	0.87

Sinco Pharmaceutical Holdings's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1399.165	/	1585.91
	=	0.88

Sinco Pharmaceutical Holdings (HKSE:06833) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Sinco Pharmaceutical Holdings's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1399.165 / 1585.91
	=	11.78 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Sinco Pharmaceutical Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN

Website

https://www.sinco-pharm.com

Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines